NuGen Medical Devices Provides Update on Health Canada Licence Application

Health Canada’s refusal halts InsuJet sales in Canada, stalling NuGen’s domestic ambitions.

What the company is saying

NuGen Medical Devices Inc. reports that Health Canada has issued a Notice of Refusal for its Class II medical device licence application no. 407982 for the InsuJet needle-free insulin injection system. The company’s previous Canadian licence had lapsed, and sales in Canada were already halted during the review; this refusal means sales and supply remain stopped. Health Canada found the clinical evidence insufficient for safety and effectiveness under sections 11, 12, and 13 of the Canadian Medical Devices Regulations, specifically citing gaps in insulin-specific clinical performance, bioequivalence, long-term glycemic control, patient self-administration, and injection performance. NuGen emphasizes that this refusal only affects the Canadian application and does not alter InsuJet’s regulatory status in other countries, where commercial activities continue subject to local rules. The company highlights that no recall is required for devices previously lawfully sold in Canada and that existing Canadian users may continue using their devices. CEO Liang Lin expresses disappointment but frames the feedback as a guide for future clinical evidence generation and regulatory engagement. The company states its intention to incorporate Health Canada’s requirements into the development of its next-generation injector platform, contingent on available funding and further regulatory feedback.

What the data suggests

The announcement provides clear regulatory facts: Health Canada’s Notice of Refusal blocks NuGen’s InsuJet from the Canadian market until new, more robust clinical evidence is generated. Application number 407982 and the cited regulatory sections (11, 12, and 13) anchor the decision in specific legal requirements. The deficiencies are detailed and substantive, spanning clinical performance, safety, and patient usability. No recall is mandated for previously sold devices, and current users are unaffected, limiting immediate legal or reputational fallout. The company’s continued international operations are referenced but not quantified; there are no disclosed figures for sales, revenue, or market share in Canada or abroad. The only explicit financial signal is that future clinical work is ‘subject to available funding,’ indicating potential capital constraints. The data is transparent about regulatory process and next steps but omits any quantitative financial or operational metrics, leaving the financial impact of the Canadian halt unquantified.

Analysis

The announcement is factual and restrained, focusing on Health Canada's Notice of Refusal for the InsuJet device and the resulting halt of Canadian sales. The company's statements about future intentions—such as reviewing the refusal, engaging with regulators, and planning new clinical evidence-generation—are appropriately cautious and clearly conditional ('subject to available funding'). There is no attempt to overstate progress or minimize the setback; the language is measured and does not inflate the company's position. While the company references ongoing international activities, it does not exaggerate their scale or impact, and no unsupported claims about imminent recovery or market expansion are made. The forward-looking statements are limited to intentions and commitments to regulatory engagement, not to specific timelines or guaranteed outcomes. The only capital intensity signal is the mention of future activities being contingent on funding, which is transparently disclosed.

Risk flags

• ●Regulatory risk is high: Health Canada’s refusal is based on substantive clinical evidence gaps, and there is no guarantee that future submissions will succeed without significant new data. This creates prolonged uncertainty for Canadian market access.
• ●Financial risk is present: The company explicitly states that further clinical evidence generation is subject to available funding, suggesting that capital constraints could delay or prevent the necessary studies for reapplication.
• ●Commercial concentration risk is elevated: With Canadian sales halted and no quantified international sales data, the company’s reliance on non-Canadian markets is unmeasured, and any regulatory or commercial setbacks elsewhere could further impact overall performance.

Bottom line

NuGen Medical Devices Inc. faces a significant setback as Health Canada’s Notice of Refusal halts InsuJet sales in Canada and requires substantial new clinical evidence for any future approval. The company’s messaging is factual and measured, acknowledging the regulatory failings and outlining a conditional plan to address them, but all next steps depend on securing additional funding and regulatory guidance. There is no immediate risk to existing Canadian users, and no recall is required, but the loss of Canadian market access removes a potential revenue stream with no timeline for reinstatement. The lack of financial or operational data on international markets leaves investors unable to gauge the true impact of this setback. The most important takeaway is that NuGen’s return to the Canadian market is now a long-term prospect, contingent on overcoming both scientific and financial hurdles.

Announcement summary

(TSXV:NGMD) NuGen Medical Devices Inc. announced that Health Canada has issued a Notice of Refusal regarding the company's Class II medical device licence application no. 407982 for the InsuJet™ needle-free insulin injection system. The company's previous Canadian medical device licence had lapsed, resulting in a halt of sales and supply of InsuJet in Canada while the new application was under review. Sales and further supply of InsuJet in Canada remain halted following the Notice of Refusal. Health Canada determined that the clinical evidence submitted was insufficient to demonstrate compliance with safety and effectiveness requirements under sections 11, 12, and 13 of the Canadian Medical Devices Regulations. Specific deficiencies identified by Health Canada include the need for additional evidence on insulin-specific clinical performance, bioequivalence or alternative evidence supporting safety and effectiveness of insulin therapy using the device, longer-term glycemic control and safety endpoints, reliable patient self-administration, and injection performance. The Notice of Refusal applies only to the Canadian application and does not affect the regulatory status of InsuJet in jurisdictions outside Canada. NuGen continues to maintain registrations and commercial activities for InsuJet in several international markets, subject to local regulatory requirements. The Notice of Refusal does not require a recall of InsuJet devices previously lawfully imported and sold in Canada while the licence was active. Existing Canadian users are not required to discontinue use of devices already supplied. NuGen intends to review the Notice of Refusal with its regulatory and clinical advisers and to continue discussions with Health Canada regarding the evidence required for a future submission. The company currently intends, subject to available funding, final protocol design, regulatory feedback, and other factors, to incorporate Health Canada's feedback into clinical evidence-generation activities for its next-generation needle-free injector platform. Liang Lin, Chief Executive Officer of NuGen, stated that the company is disappointed with Health Canada's decision but will consider the requirements as part of its planned clinical program for next-generation needle-free technology. The company remains committed to working with regulatory and clinical partners to address Health Canada's requirements and pursue a path back to the Canadian market.

Disagree with this article?